Nanotechnology promotes the full-thickness diabetic wound healing effect of recombinant human epidermal growth factor in diabetic rats

Wound Repair and Regeneration

Volumn 18, Issue 5, 2010, Pages 499-505

  Chu, Yuejie ^a   Yu, Demin ^a   Wang, Penghua ^a   Xu, Jun ^a   Li, Daiqing ^a   Ding, Min ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CYCLINE; NANOPARTICLE; PHOSPHATE BUFFERED SALINE; POLYGLACTIN; RECOMBINANT EPIDERMAL GROWTH FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIABETES MELLITUS; EMULSION; ENCAPSULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GRANULATION TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOLOGY; MOUSE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SKIN FIBROBLAST; TRANSMISSION ELECTRON MICROSCOPY; WOUND HEALING; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMAL GROWTH FACTOR; FOLLOW-UP STUDIES; HUMANS; NANOCAPSULES; NANOTECHNOLOGY; RATS; RECOMBINANT PROTEINS; SKIN DISEASES; TREATMENT OUTCOME; ULCER; WOUND HEALING;

EID: 77956621406     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2010.00612.x     Document Type: Article

References (21)

1. Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg 2002 19: 483 491.
2. Lobmann R, Schultz G, Lehnert H. Molecular fundamentals of wound healing in diabetic foot syndrome. Med Klin (Munich) 2003 98: 292 301.
3. Okumura K, Kiyohara Y, Komada F, Iwakawa S, Hirai M, Fuwa T. Improvement in wound healing by epidermal growth factor (EGF) ointment. I. Effect of nafamostat, gabexate, or gelatin on stabilization and efficacy of EGF. Pharm Res 1990 7: 1289 1293.
4. Liu XY, Chang J, Guo YS. Study of drup-loaded immunonanoparticles targeting to lens epithelial cells. Chinese J Biomed Eng 2004 23: 583 588.
5. Sun J, Dai Z, Zhao Y, Chen GQ. In vitro effect of oligo-hydroxyalkanoates on the growth of mouse fibroblast cell line L929. Biomaterials 2007 28: 3896 3903.
6. Goodridge D, Trepman E, Sloan J, Strain LA, McIntyre J, Embil JM. Quality of life of adults with unhealed and healed diabetic foot ulcers. Foot Ankle Int 2006 27: 274 280.
7. Galkowska H, Wojewodzka U, Olszewski WL. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Repair Regen 2006 14: 558 565.
8. Bennett SP, Griffiths GD, Schor AM, leese GP, Schor SL. Growth factors in the treatment of diabetic foot ulcers. Br J Surg 2003 90: 133 146.
9. Mohan VK. Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers. Diabetes Res Clin Pract 2007 78: 405 411.
10. Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA Cuban Citoprot-P Study Group. Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation. Int Wound J 2007 4: 333 343.
11. He C, Hughes MA, Cherry GW, Arnold F. Effects of chronic wound fluid on the bioactivity of platelet-derived growth factor in serum-free medium and its direct effect on fibroblast growth. Wound Repair Regen 2001 9: 305 313.
12. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems. Nat Med 2006 2: 53 65.
13. Kim TH, Lee H, Park TG. Pegylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials 2002 23: 2311 2317.
14. Cleland JL, Duenas ET, Park A, Daugherty A, Kahn J, Kowalski J, Cuthbertson A. Development of poly-(d,l-lactide-coglycolide) microsphere formulations containing recombinant human vascular endothelial growth factor to promote local angiogenesis. J Controlled Release 2001 72: 13 24.
15. Pean JM, Boury F, Venier-Julienne MC, Menei P, Proust JE, Benoit JP. Why does PEG400 co-encapsulation improve NGF stability and release from PLGA biodegradable microspheres? Pharm Res 1999 16: 1294 1299.
16. Kang F, Jiang G, Hinderliter A, DeLuca PP, Singh J. Lysozyme stability in primary emulsion for PLGA microsphere preparation: effect of recovery methods and stabilizing excipients. Pharm Res 2002 19: 629 633.
17. Loo JSC, Ooi CP, Boey FYC. Degradation of poly (lactide-co-glycolide) (PLGA) and poly(l-lactide) (PLLA) by electron beam radiation. Biomaterials 2005 26: 1359 1367.
18. Anderson JM, Shive SM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Delivery Rev 1997 28: 5 24.
19. Galkowska H, Olszewsk WL, Wojewodzka U, Mijal J, Filipiuk E. Expression of apoptosis- and cell cycle-related proteins in epidermis of venous leg and diabetic foot ulcers. Surgery 2003 134: 213 220.
20. Sun TZ, Fu XB, Gu XM. The Significance of changes in PCNA expression in hypertrophic scars and chronic ulcers. Chinese J Plastic Surg 2002 18: 232 233.
21. Prelich G, Tan C K, Kostura M, Methews MB, So AG, Downey KM, Stillman B. Functional identity proliferating cell nuclear antigen and a DNA polymerase-delta auxiliary protein. Nature 1987 326: 517 520.